Why Women Get Migraine More Than Men: The Hormonal and Neurological Explanation

Migraine affects women approximately three times more often than men. This disparity is one of the most consistent findings in headache epidemiology, replicated across cultures, geographic regions, and study methodologies. It is not explained by differences in pain tolerance, healthcare-seeking behavior, or willingness to report symptoms. It reflects genuine biological differences in migraine susceptibility that are directly tied to the hormonal environment of the female reproductive system.

Understanding why migraine disproportionately affects women is not merely an academic exercise. It has direct implications for how migraine is evaluated and treated in women, why certain periods of life carry dramatically higher attack frequency, and why some of the most effective migraine management strategies for women involve attention to the hormonal cycle.

The Hormonal Turning Point

Before puberty, migraine affects boys and girls at approximately equal rates. The dramatic shift in prevalence occurs at puberty, when female hormonal cycling begins and migraine rates in girls increase sharply. The onset of regular menstrual cycles marks the beginning of a cyclical exposure to hormonal fluctuations that profoundly influence migraine susceptibility throughout the reproductive years.

The rise in migraine prevalence at puberty directly implicates the hormonal changes of female reproductive development as a precipitating factor. The same pattern is seen in reverse at menopause, when many women experience a reduction in migraine frequency as hormonal cycling ceases. The correlation between female reproductive hormones and migraine risk is one of the most robust observations in migraine epidemiology.

Estrogen and the Migraine Brain

Estrogen is the primary sex hormone implicated in the hormonal modulation of migraine. Estrogen exerts broad effects on the central nervous system, influencing neuronal excitability, serotonergic signaling, and the sensitivity of the trigeminovascular system. In the context of migraine, the most significant effect of estrogen is on neuronal excitability and the threshold for triggering cortical spreading depression and trigeminovascular activation.

High estrogen levels appear to have a protective or stabilizing effect on migraine susceptibility. Low estrogen levels, and particularly rapid drops in estrogen, are associated with increased migraine susceptibility. This explains the phenomenon of menstrual migraine, in which attacks cluster in the days just before and at the start of menstruation, when estrogen levels fall sharply following the luteal phase of the cycle.

Estrogen also modulates serotonin signaling, which is relevant because serotonin plays a role in pain modulation and in the regulation of the trigeminovascular system. Fluctuating estrogen levels produce corresponding fluctuations in serotonin availability and receptor sensitivity that may lower the migraine threshold.

Menstrual Migraine

Menstrual migraine, defined as migraine that occurs predictably in the perimenstrual window from two days before menstruation to three days after its onset, affects approximately half of women with migraine. A subset of these women experience pure menstrual migraine, in which attacks occur exclusively during this window.

Menstrual migraine attacks tend to be more severe, longer in duration, and more resistant to standard acute treatment than attacks at other times of the cycle. This is consistent with the role of estrogen withdrawal as a more powerful trigger than other influences and with the distinct neurological state associated with the perimenstrual period.

The hormonal basis of menstrual migraine has treatment implications. Strategies that stabilize estrogen levels around the perimenstrual window, including the use of supplemental estrogen during the luteal phase, can significantly reduce the frequency and severity of menstrual migraine in women who respond to this approach. These strategies require individualized assessment by a clinician experienced in hormonal migraine management.

Pregnancy and Postpartum

The hormonal changes of pregnancy produce dramatic shifts in migraine pattern for many women. During the second and third trimesters, when estrogen levels are sustained at high levels, approximately seventy percent of women with migraine experience improvement in attack frequency and severity. This natural experiment confirms the relationship between stable high estrogen and reduced migraine susceptibility.

The first trimester, when hormonal levels are rising but unstable, may be associated with worsened migraine for some women. The postpartum period, characterized by a dramatic drop in estrogen following delivery, is a high-risk window for migraine attacks, particularly in women who breastfeed and have delayed return of hormonal cycling.

Perimenopause, Menopause, and Beyond

Perimenopause, the transitional period leading up to menopause, is associated with increased migraine frequency in many women. During this period, estrogen levels become increasingly variable, with larger fluctuations from high to low creating repeated episodes of estrogen withdrawal that can trigger attacks.

The situation typically stabilizes after menopause, when estrogen levels settle at a consistently low level. Many postmenopausal women experience a reduction in migraine frequency. Women who use hormone replacement therapy after menopause may find that the form and delivery method of hormone therapy significantly influences their migraine pattern. Our dedicated guide to migraine and menopause covers this transition in more depth, including how aura status and surgical versus natural menopause change what to expect.

Neurological differences between men and women with migraine extend beyond hormones. Genetic studies have identified sex-specific genetic associations with migraine risk. Neuroimaging research has documented differences in brain structure and function between men and women with migraine. The interaction between genetic susceptibility, hormonal environment, and neurological organization creates a migraine phenotype in women that is distinct in its prevalence, pattern, and hormonal modulation.